Zai Lab Current Ratio 2016-2022 | ZLAB
Zai Lab current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
| Zai Lab Current Ratio Historical Data |
| Date |
Current Assets |
Current Liabilities |
Current Ratio |
| 2022-09-30 |
$1.21B |
$0.16B |
7.78 |
| 2022-06-30 |
$1.34B |
$0.17B |
7.91 |
| 2022-03-31 |
$1.39B |
$0.16B |
8.99 |
| 2021-12-31 |
$1.50B |
$0.19B |
7.78 |
| 2021-09-30 |
$1.62B |
$0.11B |
14.46 |
| 2021-06-30 |
$1.81B |
$0.19B |
9.33 |
| 2021-03-31 |
$1.05B |
$0.09B |
11.32 |
| 2020-12-31 |
$1.22B |
$0.10B |
12.40 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-06-30 |
$0.49B |
$0.06B |
8.57 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-12-31 |
$0.29B |
$0.05B |
6.27 |
| 2019-09-30 |
$0.33B |
$0.04B |
8.02 |
| 2019-06-30 |
$0.40B |
$0.05B |
8.74 |
| 2018-12-31 |
$0.27B |
$0.05B |
5.51 |
| 2017-12-31 |
$0.23B |
$0.01B |
19.11 |
| 2017-06-30 |
$0.09B |
$0.01B |
9.76 |
| 2016-12-31 |
$0.08B |
$0.01B |
16.26 |
| 2015-12-31 |
$0.01B |
$0.00B |
3.36 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$3.925B |
$0.144B |
|
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
|
